EUVIMEDEUVIMED entdecken
Crossref

Pre-exposure Prophylaxis Use History in People With Antiretroviral Resistance at HIV Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015–2022

Kavita Misra iD, Jamie S Huang, Chi-Chi N Udeagu, Lisa Forgione, Qiang Xia iD, Lucia V Torian

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciad699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Kavita Misra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Bureau of Hepatitis, HIV and STIs, New York City Department of Health and Mental Hygiene, Queens, New York, USA. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis, Drug Resistance, Viral, Anti-HIV Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Drug resistance may be acquired in people starting human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) during undiagnosed infection. Population-based estimates of PrEP-related resistance are lacking.

Methods

We used New York City surveillance and partner services data to measure the effect of PrEP use (tenofovir disoproxil fumarate/tenofivir alafenamide fumarate with emtricitabine) history on the baseline prevalence of M184I/V mutations in people with HIV diagnosed in 2015–2022. PrEP use was categorized as “recent” (defined as PrEP stopped ≤90 days before diagnosis), “past” (PrEP stopped >90 days before diagnosis), or “no known use.” Resistance-associated mutations were determined using the Stanford algorithm. We used log binomial regression to generate the adjusted relative risk (aRR) of M184I/V by PrEP use history in people with or without acute HIV infection (AHI).

Results

Of 4246 people with newly diagnosed HIV and a genotype obtained within ≤30 days of diagnosis, 560 (13%) had AHI; 136 (3%) reported recent and 124 (35%) past PrEP use; and 98 (2%) harbored M184I/V. In people with AHI, recent PrEP use was associated with a 6 times greater risk of M184I/V than no known use (aRR, 5.86 [95% confidence interval, 2.49–13.77]). Among people without AHI, the risk of M184I/V in recent users was 7 times that in people with no known use (aRR, 7.26 [95% confidence interval, 3.98–13.24]), and in past users, it was 4 times that in those with no known use (4.46 [2.15–9.24]).

Conclusions

PrEP use was strongly associated with baseline M184I/V in New York City, regardless of AHI status. Ordering a nucleic acid test when indicated after assessment of exposure, antiretroviral history, and AHI symptoms can decrease PrEP initiation in people with undetected infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPre-Exposure ProphylaxisDrug Resistance, ViralAnti-HIV AgentsHumansNew York CityMaleAdultFemaleMiddle AgedHIV-1Young AdultMutationTenofovirPrevalence

Stichwörter der Autor:innen

HIVUnited Statesdrug resistancepreexposure prophylaxisresistance associated mutations

Substanzen

Anti-HIV AgentsTenofovir

Autor:innen und Institutionen

  • Bureau of Hepatitis, HIV and STIs, New York City Department of Health and Mental Hygiene, Queens, New York, USA.

ORCID-Profile: Kavita Misra, Qiang Xia

Zitieren

APA

Misra, K., Huang, J. S., Udeagu, C. N., Forgione, L., Xia, Q., & Torian, L. V. (2024). Pre-exposure Prophylaxis Use History in People With Antiretroviral Resistance at HIV Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015–2022. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad699

Vancouver

Misra K, Huang JS, Udeagu CN, Forgione L, Xia Q, Torian LV. Pre-exposure Prophylaxis Use History in People With Antiretroviral Resistance at HIV Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015–2022. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad699

BibTeX
@article{Misra2024,
  author = {Misra, Kavita and Huang, Jamie S and Udeagu, Chi-Chi N and Forgione, Lisa and Xia, Qiang and Torian, Lucia V},
  title = {Pre-exposure Prophylaxis Use History in People With Antiretroviral Resistance at HIV Diagnosis: Findings From New York City HIV Surveillance and Partner Services, 2015–2022},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciad699}
}
Kostenlos starten →